Neurol. praxi. 2016;17(3):92-94 | DOI: 10.36290/neu.2016.032

Cognitive impairment in endocrine and renal disorders

Mgr. Eva Bolceková1,2, doc. MUDr. Robert Rusina Ph.D.2, 3
1 Národní ústav duševního zdraví, Klecany
2 Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN, Praha
3 Neurologické oddělení, Thomayerova nemocnice, Praha

Diagnosing endocrine disorders as the underlying cause of cognitive symptoms has essential importance since adequate treatment of hormonal dysfunction may improve neurological manifestations. Hypothyroidism may cause decrease in cognition very similar to depression, with a very good effect of substitution therapy. Therefore thyroid hormone level dosage is useful in dementia screening. A rare but treatable cause of rapid progressive dementia is Hashimoto´s encephalopathy. Hyperparathyroidism is often associated with psychiatric features and encephalopathy. Postmenopausal estrogen deficiency is related to increased risk of Alzheimer’s disease, the benefit of preventive hormonal substation therapy, however, remains controversial. Cognitive symptoms in chronic renal disease include mainly uremic encephalopathy and it is important to differentiate manifestation of kidney disease itself and complications due to dialysis.

Keywords: hypothyroidism, Hashimoto´s encephalopathy, hyperparathyroidism, estrogen, menopause, uremic encephalopathy

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bolceková E, Rusina R. Cognitive impairment in endocrine and renal disorders. Neurol. praxi. 2016;17(3):92-94. doi: 10.36290/neu.2016.032.
Download citation

References

  1. Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab 2014; 40: 331-337. Go to original source... Go to PubMed...
  2. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008; 358: 2594-2605. Go to original source...
  3. Burn J, Bates D. Neurology and the kidney J Neurol Neurosurg Psychiatry 1998; 65: 810-821. Go to original source...
  4. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16: 203-204. Go to original source... Go to PubMed...
  5. Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med 1998; 158: 1413-1418. Go to original source...
  6. Elias MF, Dore GA, Davey A. Kidney disease and cognitive function. Contrib Nephrol 2013; 179: 42-57. Go to original source... Go to PubMed...
  7. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM; WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013; 173: 1429-1436. Go to original source...
  8. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings. Mayo Clin Proc. 2010; 85: 427-432. Go to original source...
  9. Henderson VW. The neurology of menopause. Neurologist. 2006; 12: 149-159. Go to original source... Go to PubMed...
  10. Ishii M. Neurologic complications of nondiabetic endocrine disorders. Continuum (Minneap Minn) 2014; 20: 560-579. Go to original source...
  11. Joffe RT, Pearce EN, Hennessey JV, Ryan JJ, Stern RA. Subclinical hypothyroidism, mood, and cognition in older adults: a review. Int J Geriatr Psychiatry 2013; 28: 111-118. Go to original source...
  12. Kowdley KV, Coull BM, Orwoll ES. Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. Am J Med Sci 1999; 317: 273-277. Go to original source...
  13. Lobo RA. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab 2013; 98: 1771-1780. Go to original source...
  14. Lourida I, Thompson-Coon J, Dickens CM, Soni M, Kuźma E, Kos K, Llewellyn DJ. Parathyroid hormone, cognitive function and dementia: a systematic review. PLoS One 2015; 10: e0127574. Go to original source... Go to PubMed...
  15. Manyam BV. What is and what is not 'Fahr's disease'. Parkinsonism Relat Disord 2005; 11: 73-80. Go to original source...
  16. Ojo O, Brooke J. Evaluating the Association between Diabetes, Cognitive Decline and Dementia. Int J Environ Res Public Health 2015;12: 8281-8294. Go to original source... Go to PubMed...
  17. Olmez I, Moses H, Sriram S, Kirshner H, Lagrange AH, Pawate S. Diagnostic and therapeutic aspects of Hashimoto's encephalopathy. J Neurol Sci 2013; 331: 67-71. Go to original source...
  18. Seipelt M, Zerr I, Nau R, Mollenhauer B, Kropp S, Steinhoff BJ, Wilhelm-Gössling C, Bamberg C, Janzen RW, Berlit P, Manz F, Felgenhauer K, Poser S. Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999; 66: 172-176. Go to original source...
  19. Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, Cosman F, Silverberg SJ. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009; 94: 1951-1958. Go to original source...
  20. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153: 747-753. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.